Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects

• Published in: Annals of nuclear medicine Vol. 37; no. 5; pp. 300 - 309
• Main Authors: Miyamoto, Masaomi, Okuyama, Chio, Kagawa, Shinya, Kusano, Kuninori, Takahashi, Masaaki, Takahata, Keisuke, Jang, Ming-Kuei, Yamauchi, Hiroshi
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.05.2023; Springer Nature B.V
• Subjects: Adult; Alzheimer's disease; Animal models; Blood; Brain; Dosimeters; Dosimetry; East Asian People; EKG; Electrocardiography; Evaluation; Fibrils; Gallbladder; Humans; Imaging; Injection; Intestine; Intravenous administration; Large intestine; Liver; Male; Males; Medicine; Medicine & Public Health; Middle Aged; Neurodegenerative diseases; Nuclear Medicine; Organs; Original; Original Article; Pharmacokinetics; Positron emission; Positron-Emission Tomography - methods; Radiation; Radiation dosage; Radiology; Radiometry; Radiopharmaceuticals - pharmacokinetics; Safety; Tau protein; Tissue Distribution; Vital signs; Young Adult; Tau PET ligand; Effective dose; Pharmacokinetics; Florzolotau (18F) (APN-1607, PM-PBB3); Dosimetry study
• ISSN: 0914-7187; 1864-6433; 1864-6433
• DOI: 10.1007/s12149-023-01828-x

Objective Abnormal aggregation of tau in the brain is a major contributing factor in various neurodegenerative diseases. Florzolotau (18F) (florzolotau, APN-1607, PM-PBB3) has been shown to be a probe for tau fibrils in an animal model and patients with Alzheimer’s disease and those with non-Alzheimer’s disease tauopathies. The objective of this study is to evaluate the safety, pharmacokinetics, and radiation dose following a single intravenous administration of florzolotau in healthy Japanese subjects. Methods Three healthy male Japanese subjects aged between 20 and 64 were enrolled in this study. Subjects were determined to be eligible based on the screening assessments at the study site. Subjects received a single intravenous dose of 195.0 ± 0.5 MBq of florzolotau and underwent the whole-body PET scan 10 times in total to calculate absorbed doses to major organs/tissues and effective dose. Radioactivities in whole blood and urine were also measured for pharmacokinetic evaluation. Absorbed doses to major organs/tissues and effective dose were estimated using the medical internal radiation dose (MIRD) method. Vital signs, electrocardiography (ECG), and blood tests were done for safety evaluation. Results The intravenous injection of florzolotau was well tolerated. There were no adverse events or clinically detectable pharmacologic effects related to the tracer in any subjects. No significant changes in vital signs and ECG were observed. The highest mean initial uptake at 15 min after injection was in the liver (29.0 ± 4.0%ID), intestine (4.69 ± 1.65%ID), and brain (2.13 ± 0.18%ID). The highest absorbed dose was 508 μGy/MBq of the gallbladder wall, followed by the liver of 79.4 μGy/MBq, the pancreas of 42.5 μGy/MBq, and the upper large intestine of 34.2 μGy/MBq. The effective dose was calculated as 19.7 μSv/MBq according to the tissue weighting factor reported by ICRP-103. Conclusion Florzolotau intravenous injection was well tolerated in healthy male Japanese subjects. The effective dose was determined as 3.61 mSv when 185 MBq florzolotau was given.